MARY ANN LIEBERT, INC./GENETIC ENGINEERING NEWS
A new review in the peer-reviewed journal Psychedelic Medicine describes the complex pharmacology of methylenedioxy amphetamine analogues, or MDXX drugs, and how they may help treat autism spectrum disorder (ASD). Click here to read the article now.
There are no approved pharmacotherapeutics for global symptoms of ASD. Drugs that have pro-social effects, such as MDMA and its analogues, may be beneficial in treating the social anxiety and social avoidance that are major complications of ASD.
In the article titled “Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues As Novel Treatments for Autism Spectrum Disorder,” William Fantegrossi, PhD, from the University of Arkansas for Medical Sciences College of Medicine, and coauthors, discuss the roles of various drug-binding sites, metabolic enzymes, and chemical structure-activity relationships that mediate these substances’ pharmacological and toxicological effects.
The investigators concluded that “the MDXX drugs represent a fruitful chemical space for developing clinically effective and relatively safer molecules and formulations for treating ASD.”
Psychedelic Medicine is the first peer-reviewed journal to publish original research papers on every aspect of psychedelic medicine, including basic science, clinical, and translational research, as well as medical applications. This journal provides a vital resource for clinicians and patients alike who are invested in the potential efficacy of psychedelic drugs currently undergoing research in preclinical and clinical studies as an alternative or supplement to traditionally manufactured pharmaceuticals to treat depression, anxiety, addiction, demoralization, and other mental health conditions. Visit the Psychedelic Medicine website to learn more.
About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.
Leave a Reply